May 14, 2008 - Akorn-Strides, LLC today announced the approval of an ANDA for Flumazenil Injection USP, 0.1 mg/mL, packaged in 5 mL and 10 mL Multiple Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ:AKRX) and Strides Arcolab Limited (NSE:STAR) (BSE:532531). The primary mission for the Joint Venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.
Flumazenil Injection is indicated for the complete or partial reversal of the sedative effects of benzodiazepines. Recent IMS data estimates an annual market size of approximately $14 million.
The details can be read here.
No comments:
Post a Comment